Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia $(FA)$ in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.